CURRENT TRENDS AND PROSPECTS OF THE RUSSIAN PHARMACEUTICAL INDUSTRY AND THE FOREIGN EXPERIENCE

• Main Author: Z. A. Mamedyarov
• Format: Article
• Language: Russian
• Published: Nauka 2018-01-01
• Series: Modernizaciâ, Innovaciâ, Razvitie
• Subjects: pharmaceutical industry; innovation; state support for pharma; pharmaceutical import; russian pharma
• Online Access: https://www.mir-nayka.com/jour/article/view/799

Purpose: the purpose of this article is to study the current state of the pharmaceutical industry in Russia, to identify trends in Russian pharmaceutical market, and to provide preliminary analysis of the state support policy for pharmaceuticals in Russia, focusing on the federal target program "Pharma-2020".Methods: the study is based on a quantitative study of the characteristics and trends of the Russian pharmaceutical market. The emphasis was put on the period 2008–2017. The volume of the market, the structure of imports and exports are considered, and expenditures under the federal program "Pharma-2020" are studied. A qualitative comparative comparison with the tendencies of the global development of the industry is conducted and recommendations are made on further stimulating the growth of the pharma industry in Russia.Results: in the past 5 years, the pharmaceutical industry in Russia did receive special attention from the government, significant funds have been allocated for to support domestic producers, and import substitution policies have been launched. Financial results of the industry show slight improvement in a number of indicators: the market share of domestic medicines is growing, the generics production increased, production standards became tighter controlled. Nevertheless, Russia remains on the periphery of the world pharmaceutical science, import retains two thirds of the market share by value, while innovative novel drugs are now launched primarily by MNEs from the US and the EU.Conclusions and relevance: the challenges and development factors of Russia's pharmaceutical industry identified in this research require effective regulatory tools. First of all, it is necessary to reduce the gap between Russia and the developed countries in the R&D standards and their market implementation. Statistical data has showed the progress in the production of drugs from the VED list (Vital and Essential Drugs), but it is necessary to emphasize the need to update this list, provide it with the latest and innovative drugs. Annual list actualization and its expansion can play an effective role in future. In general, the Russian pharmaceutical sector is currently at its best for the entire period under review, however, the rise in international competition and the role of developing countries pose new challenges. First of all, Russia might take the best from expanding the drugs market and supporting export activity. Trade agreements and union tendencies (EAES) on the scale of Eurasia can play a larger role – Russia's advantage is the fact that the countries of the former USSR have very limited own pharmaceutical industry, whilst the demand for quality products there is growing.